Skip To Main Content
Nasdaq Biotechnology on Muck Rack

Nasdaq Biotechnology

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Nasdaq

Contact Nasdaq, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

PSD Bank Rhein-Ruhr eG

|
By Carlos Campoy, Nancy Davidson, Derek Miller, Nasdaq Biotechnology
| Sparda-Bank web.Börsenforum
* Company well-positioned for further progress and broadening of R&D pipeline * Cash resources of approximately $455 million as of December 31, 2023 (unaudited) * Expected cash runway, including proceeds from recent private placement, into 2H 2027 * Top-line data readout from the Phase 3 trial evaluating zanidatamab in HER2- positive gastroesophageal adenocarcinoma (GEA), HERIZON-GEA-01, expected in 2024 * Expected regulatory reviews ongoing during 2024 for zanidatamab in second- line biliary...
Open in Who Shared View Duplicates (195) Issue with article?
See all 1 articles